Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Clyra Medical Technologies [Member] Common Stock [Member]	Clyra Medical Technologies [Member] Additional Paid-in Capital [Member]	Clyra Medical Technologies [Member] Retained Earnings [Member]	Clyra Medical Technologies [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technologies [Member] Noncontrolling Interest [Member]	Clyra Medical Technologies [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Common Stock [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Additional Paid-in Capital [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Retained Earnings [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] AOCI Attributable to Parent [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Noncontrolling Interest [Member]	BioLargo Energy Technologies, Inc (BETI) [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021													255,893,726
Balance at Dec. 31, 2021													$ 171,000	$ 143,718,000	$ (139,121,000)	$ (115,000)	$ (3,720,000)	$ 933,000
Sale of stock for cash (in shares)													6,703,789
Sale of stock for cash													$ 4,000	1,198,000	0	0	0	1,202,000
Issuance of common stock for services (in shares)													86,752
Issuance of common stock for services													$ 0	17,000	0	0	0	17,000
Stock option compensation expense	$ 0	$ 141,000	$ 0	$ 0	$ 0	$ 141,000							0	660,000	0	0	0	660,000
Noncontrolling interest allocation													0	(528,000)	0	0	528,000	0
Net loss													0	0	(1,652,000)	0	108,000	(1,544,000)
Foreign currency translation													$ 0	0	0	(8,000)	0	(8,000)
Balance (in shares) at Mar. 31, 2022													262,684,267
Balance at Mar. 31, 2022													$ 176,000	145,205,000	(140,773,000)	(123,000)	(3,085,000)	1,400,000
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Sale of stock for cash (in shares)													4,201,402
Sale of stock for cash													$ 3,000	797,000	0	0	0	800,000
Issuance of common stock for services (in shares)													930,490
Issuance of common stock for services													$ 1,000	206,000	0	0	0	207,000
Issuance of common stock in exchange for Clyra shares (in shares)													527,983
Stock option compensation expense													$ 0	195,000	0	0	0	195,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	61,000	0	0	0	61,000
Warrant issued for interest													0	30,000	0	0	0	30,000
Clyra – sales of Series A Preferred Stock	0	0	0	0	225,000	225,000	$ 0	$ 0	$ 0	$ 0	$ 550,000	$ 550,000
Clyra – Series A Preferred Stock – dividend	$ 0	$ 0	$ 0	$ 0	$ (27,000)	$ (27,000)
Noncontrolling interest allocation													0	467,000	0	0	(467,000)	0
Net loss													0	0	(247,000)	0	(247,000)	(494,000)
Foreign currency translation													$ 0	0	0	(6,000)	0	(6,000)
Balance (in shares) at Mar. 31, 2023													284,122,581
Balance at Mar. 31, 2023													$ 190,000	$ 150,191,000	$ (143,841,000)	$ (155,000)	$ (2,833,000)	$ 3,552,000